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Background: A large number of patients with sicca syndrome not fulfilling Sjögren's syndrome (SS) classification criteria, present manifestations of autoimmunity, like arthritis, Raynaud's, rash or hematologic disturbances, and have anti-nuclear antibodies, lacking however more specific antibodies. The designation Undifferentiated Connective Tissue Disease was coined to refer to those patients, and some will eventually progress to a definite disease, of which SS would be a likely candidate. Immune cell disturbances could be progression markerr, since diseases like pSS have distinct lymphocyte profiles. Objectives: We aim to study the circulating lymphocyte subsets in non-Sjögren sicca patients (n-SS), and compare them with pSS and healthy controls. Methods: We included 65 n-SS patients, 53 pSS patients (2002 AECG criteria) and 22 healthy controls. Lymphocyte subsets were characterized by flow cytometry, including follicular and regulatory T cells and naïve, mature, memory, plasmablasts and regulatory B cells. Statistical analysis was performed with GraphPad, and significance was considered for p<0.05 Results: Comparing to controls, n-SS patients had lower counts of T cells (p=0.016), with lower CD4 (p=0.0028), however that difference was not as pronounced as between SS and controls. n-SS patients had higher percentages of CD4 (p=0.0005) and lower CD8 percentages (p=0.0009) than pSS. Additionally, there was a decrease in absolute counts of Tregs (p=0.0028) in n-SS patients compared to controls, which was less pronounced than the comparison between SS and controls (p=0.0008). Th17 cells were decreased in SS compared to controls (p=0.0005), but not in-SS patients. Compared with controls, both n-SS and SS patients presented decreased absolute count (p=0.0001 and p<0,0001, respectively) of CXCR5 + Tfh cells, with no differences between n-SS and SS patients. However, higher levels of IL21 + CD4 T cells and Tfh1 cells were found comparing SS patients with both controls (p=0,0209 and p=0,0092 respectively) and n-SS patients (p=0,0051 and 0,0028 respectively). Absolute counts of memory, unswitched and switched memory cells in n-SS patients present intermediate levels between controls with significantly higher levels, and SS patients with significantly lower levels. Accordingly, using the Bm1-5 classification, we have found decreased Bm1 (p=0.004), eBm5 (Abs, p=0.0273) and Bm5 cells (Abs, p=0.0444) in n-SS patients compared to controls. Though not significant, there was an increase in eBm5 (Abs, p=0.063) and Bm5 cells (Abs, p=0.05) in n-SS compared to SS patients. Again, CD24 + CD27 + Bregs were also decreased in n-SS patients compared to controls (p=0.036), but increased in n-SS compared to SS patients (p=0,0007). Conclusions: Our data showed that n-SS patients present immune disregulation, represented by alterations in the B cell compartment but also in Tfh subset, known to modulate the humoral immune response. Although less pronounced, these modifications resemble the ones found in SS patients. Wether n-SS is a stage in the evolution to SS remains to be clarified. The identification of a characteristic disregulation of the immune system in n-SS could be usefull for diagnostic and prognostic purposes. Background: High-dose cyclophosphamide (CFA) is used for treatment of patients with severe manifestations of systemic autoimmune diseases. The knowledge about the effect of CFA on circulating cell populations in these diseases is still limited. Objectives: To identify the effect of a single dose of CFA on circulating cell populations in patients with vasculitides and autoimmune systemic diseases. Methods: We immunophenotyped T lymphocytes (CD3, CD4, CD8, CD25, CD127, HLA-DR), B lymphocytes (CD19, CD20, CD27), NK cells (CD3, CD16, CD56, CD69), neutrophils (CD15, CD11b, CD16, CD54, CD62L, CD64), and monocytes (CD11b, CD14, CD16, CD64, HLA-DR) using 6-color cytometer BD FACSCanto II (Becton Dickinson) in peripheral blood of patients with vasculitides (n=6) and systemic disorders of connective tissue (n=6). From each patient, we obtained paired samples before and one month after a single CFA dose. Statistical tests were performed using GraphPad Prism (GraphPad Software, Inc). P-value <0.05 was considered as significant. Results: Single dose of CFA resulted in increase of percentage of CD8+ T lymphocytes (P=0.002), leading to marked decrease of CD4+/CD8+ ratio (P=0.009). Except three patients, overall percentage of neutrophils decreased after the treatment (P=0.01). Although CFA pulse did not influence the percentage of NK cells, the percentage of NK cells carrying stimulatory receptor CD69 increased after CFA (P=0.037). Similarly, CFA enhanced the percentage of co-stimulatory molecule CD27 on B lymphocytes (P=0.048). Among subsets of monocytes, CFA treatment increased percentage of CD14-CD16+ monocytes (P=0.006) and increased expression (MFI) of Fc fragment CD64 (P=0.02). Moreover, increase of HLA-DR was observed on CD14-CD16+ monocytes (P=0.037). The investigations whether the changes in immune cell subpopulations in treated patients have prognostic potential are ongoing. Conclusions: Single dose of CFA resulted in increase of CD8+ T lymphocytes, activation of NK, B lymphocytes and monocytes as well as in some patients decrease in neutrophil counts. Further investigation of selected markers may lead to identification of new prognostic markers and predict the effectiveness of the treatment.
